Pyxis Oncology (PYXS) Net Cash Flow (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Net Cash Flow data on file, last reported at $6.5 million in Q4 2025.

• On a quarterly basis, Net Cash Flow fell 12.32% year-over-year to $6.5 million in Q4 2025; TTM through Dec 2025 was -$4.0 million, a 140.62% decrease from a year earlier, with the FY2025 full-year figure at -$4.1 million, down 141.3% from the prior year.
• Net Cash Flow for Q4 2025 stood at $6.5 million, up from -$1.8 million in the prior quarter.
• Over the last five years, Net Cash Flow for PYXS reached as high as $142.7 million in Q4 2021 and fell as low as -$126.2 million in Q1 2023.
• Historically, Net Cash Flow has averaged $132400.0 across 5 years, with a median of -$5.9 million in 2023.
• Across the five-year window, Net Cash Flow soared 4608.24% in 2021 and plunged 1417.86% in 2022, its largest moves.
• Year by year, Net Cash Flow stood at $142.7 million in 2021, then slumped by 113.48% to -$19.2 million in 2022, then soared by 73.75% to -$5.1 million in 2023, then jumped by 246.84% to $7.4 million in 2024, then dropped by 12.32% to $6.5 million in 2025.
• Per Business Quant data, the three most recent Net Cash Flow figures were $6.5 million in Q4 2025, -$1.8 million in Q3 2025, and -$2.0 million in Q2 2025.